Aprea Therapeutics (APRE)
Develops oral DNA-damage-response inhibitors for biomarker-defined solid tumors.
Something off on this page? Send us feedback.
Develops oral inhibitors targeting DNA-damage-response pathways for biomarker-defined solid tumors, advancing APR-1051 while assessing combination paths for ATRN-119. A pre-commercial model has no drug sales and depends on clinical development, regulatory progress and external partners.
Develops orally administered small-molecule inhibitors of DNA-damage-response targets for biomarker-defined solid tumors. APR-1051, a WEE1 kinase inhibitor, is the lead active program in an early clinical study, while ATRN-119, an ATR inhibitor, has paused monotherapy enrollment as combination options are assessed. APR-1602 is preclinical; the older mutant-p53 program has no ongoing trials.
Operates as a pre-commercial biotechnology company with no approved products or drug sales. Its prospective revenue model relies on clinical and regulatory success, then product sales or future collaboration and license payments; recent revenue came from research grants. Clinical trials, manufacturing, data management and other execution functions are contracted to outside organizations.
Clinical advancement depends on biomarker-selected patients, regulatory review, trial-site operations and financing. Worldwide development and commercialization rights are retained for all current candidates, while partnerships may be selected for complementary capabilities.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $41.2M · Total debt $0 · Total assets $42.3M · Shareholders' equity $38.5M
- Revenue
- $0
- Operating income
- −$4.0M
- Net income
- −$3.6M
No dividends on record.
| Institutions22 holders · as of Mar 31, 2026 | 17.82% | 2.24M shares | |
| Insiders11 holders · as of Jun 17, 2026 | 15.69% | 1.98M shares | |
| Otherremainder | 66.49% | 8.37M shares |
12.59M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Squadron Master Fund LPInstitution | 10.10% | 1.27M | 13Gfiled Apr 7, 2026 ↗ |
Soleus Private Equity Fund III, L.P.Institution | 10.10% | 1.27M | 13Gfiled Apr 1, 2026 ↗ |
Orin HirschmanInsider | 9.42% | 1.19M | 13Gfiled Apr 27, 2026 ↗ |
Aigh Capital Management LLCInstitution | 8.07% | 1.02M | 13Fas of Mar 31, 2026 |
Oren GiladInsiderdirector, officer: President/CEO | 3.13% | 393,895 | Form 4filed Mar 16, 2026 ↗ |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Mar 31, 2026 | Richard Peters | director | +247,830 | $0.3420 |
| Mar 31, 2026 | John P. Hamill | officer: SrVP/CFO/Prin Fin & Acct Ofcr | +61,956 | $0.3420 |
| Jan 30, 2026 | John P. Hamill | officer: SrVP/CFO/Prin Fin & Acct Ofcr | +11,400 | $0.8275 |
| Jan 30, 2026 | Oren Gilad | director, officer: President/CEO | +56,200 | $0.8275 |
| Dec 10, 2025 | Oren Gilad | director, officer: President/CEO | +42,918 | $0.5201 |
- Zentalis Pharmaceuticals
Leading oral WEE1 rival in biomarker-selected solid tumors.
- AstraZeneca (ADR)
Large-scale ATR inhibitor rival in biomarker-guided solid tumors.
- Acrivon Therapeutics
Dual WEE1/PKMYT1 program targets the same precision-oncology patients.
- Schrödinger
WEE1/MYT1 co-inhibitor overlaps in advanced solid tumors.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Aprea Therapeutics | $0.8200 | −2.92% | $10.2M | — | — | — | +114.2% |
| Zentalis Pharmaceuticals | $3.79 | +0.26% | $268.4M | — | — | — | — |
| AstraZeneca (ADR) | $164.21 | +1.58% | $250.67B | 24.3 | 15.2 | 4.1 | +6.4% |
| Acrivon Therapeutics | $2.15 | −0.23% | $92.0M | — | — | — | — |
| Schrödinger | $20.74 | −0.68% | $1.56B | — | — | 6.0 | +7.5% |
| Median | 24.3 | 15.2 | 5.1 | +7.0% |